Aesthetic Procedure & Treatment Guide - 28

spotlight on: pharmacy
OUR MOST POPULAR HOSPIRA PRODUCTS FOR AESTHETICS

Improved pain relief, reduced opioid consumption1
• Signiﬁcant pain relief*1 –OFIRMEV 1 g + PCA morphine demonstrated signiﬁcant pain relief vs placebo + PCA morphine (P<0.05 over 6 h)1

I T EM C O DE

ITEM DESCRIPTION

SIZE

The ﬁrst and only nd lation IV formulation nophen of acetaminophen in the US

–OFIRMEV 1 g + PCA morphine showed greater reduction in pain intensity over 24 h (SPID24)† compared to placebo + PCA morphine (P<0.001) 2 • Reduced opioid consumption*1 –OFIRMEV 1 g + PCA morphine signiﬁcantly reduced morphine consumption vs placebo + PCA morphine (−46% over 6 h, P<0.01; −33% over 24 h, P<0.01)1 –The clinical beneﬁt of reduced opioid consumption was not demonstrated • Improved patient satisfaction*1,2 –OFIRMEV 1 g + PCA morphine signiﬁcantly improved patient satisfaction vs placebo + PCA morphine at 24 h (P=0.004)‡1,2 • The ﬁrst IV antipyretic approved for children ≥2 years old 3 –Signiﬁcant fever reduction 30 minutes after initiating infusion 2 • Established safety proﬁle and well tolerated in clinical trials1-3

104-6963 104-6883 114-7523 110-6507 631-1626 258-1385 104-6560 109-7361 104-7057 104-6874 104-9909 110-3839 104-6817 104-9843 104-6822 104-6882 104-7099 104-6855 104-6867 258-7402 631-2615 631-2847 258-9815 104-6816 104-6823 104-6851 104-9943 104-8583 104-6989 258-2168 104-7765

Bupivacaine HCl 0.25% 50mL MDV Bupivacaine HCl 0.50% 50mL MDV Bupivacaine HCl Vial 0.50% 30mL Bupivacaine HCl w/Epi Vial 0. 50% 1:200m 50mL Carbocaine Inj 1% Carbocaine Inj 2% Diazepam 5mg/mL 2mL Carpuject Syringe Diazepam Inj 5mg/mL 10mL MDV Epinephrine Inj AMP 1:1000 1mL SDV Ketamine HCl Inj 50mg/mL 10mL MDV Ketorolac Inj IM 60mg/2mL 2mL SDV Lidocaine Preservative Free 1% 30mL Lidocaine HCl Inj 1% 50mL MDV Lidocaine HCl Inj 2% 50mL MDV Lidocaine w/Epi Inj 1% MDV 30mL Lidocaine w/Epi Inj 0.5% 1:200m MDV 50mL Lidocaine w/Epi Inj 1% 1:100m MDV 50mL Lidocaine w/Epi Inj 2% 1:100m MDV 30mL Lidocaine w/Epi Inj 2% 1:100m MDV 50mL Marcaine Inj 0.25% Flip Top Vial Marcaine Inj 0.5% Marcaine w/Epi 0.25% Marcaine w/Epi Inj 0.5% Normal Saline 0.9% Sodium Bicarbarbonate Inj 8.4% 50mL SDV Soduim Chloride Inj Bacteriostatic 0.9% 10mL MDV Sodium Chloride 0.9% MPF 10mL Sodium Chloride Inj 0.9% 30mL MDV Sodium Chloride Inj 0.9% 50mL SDV Sodium Chloride Irrigation 0.9% Bacteriostatic Water for Inj 30mL-Sterile

25/Box 25/Box 25/Box 25/Box 50mL MDV 50mL MDV 10/Box 10/Box 25/Box 10/Box 25/Box 25/Pkg 25/Box 25/Box 25/Box 25/Box 25/Box 25/Case 25/Box 50mL MDV 50mL MDV 50mL MDV 50mL MDV 1000mL 25/Box 25/Box 25/Box 25/Box 25/Box 250mL 25/Pkg

Dosing of OFIRMEV for adults, adolescents, and children ≥2 years old3
Dosing interval Maximum single dose Maximum total daily dose of acetaminophen (by any route)

Age group

Adults and adolescents (≥13 years old) ≥50 kg Adults and adolescents (≥13 years old) <50 kg Children ≥2 to 12 years old

Q6h

1000 mg (100 mL)*

4000 mg

OFIRMEV is indicated for the:
• Management of mild to moderate pain • Management of moderate to severe pain with adjunctive opioid analgesics

Q6h

Weight-based dose: 15 mg/kg

† 75 mg/kg

• Reduction of fever
• Minimum dosing interval is Q4h • For instructions regarding Q4h dosing, please see full Prescribing Information • No dose adjustment is required when transitioning to oral acetaminophen in adults and adolescents • OFIRMEV should be administered only as a 15-minute infusion. Administer only as directed. • Do not exceed the maximum daily dose of acetaminophen
Discontinue OFIRMEV immediately if symptoms associated with allergy or hypersensitivity occur. Do not use in patients with acetaminophen allergy. The most common adverse reactions in patients treated with OFIRMEV were nausea, vomiting, headache, and insomnia in adult patients and nausea, vomiting, constipation, pruritus, agitation, and atelectasis in pediatric patients. The antipyretic effects of OFIRMEV may mask fever in patients treated for postsurgical pain. Please see accompanying full Prescribing Information.
*Randomized, double-blind, placebo-controlled, single- and repeated-dose 24-h study (n=101). Patients received OFIRMEV 1 g + PCA morphine or placebo + PCA morphine the morning following total hip or knee replacement surgery. Primary endpoint: pain relief measured on a 5-point verbal scale over 6 h. Morphine rescue was administered as needed. †SPID24=sum of pain intensity differences, based on VAS score, from baseline, at 0 to 24 h. ‡Subjects were asked to evaluate the study treatments, overall, using a 4-point categorical scale.

*Each mL contains 10 mg of OFIRMEV. †Maximum daily dose up to 3750 mg.

10mg/mL, 100mL 24/Case 248-0337
Important Safety Information OFIRMEV should be administered only as a 15-minute infusion. Do not exceed the maximum recommended daily dose of acetaminophen. Administration of acetaminophen by any route in doses higher than recommended may result in hepatic injury, including the risk of severe hepatotoxicity and death. OFIRMEV is contraindicated in patients with severe hepatic impairment, severe active liver disease or with known hypersensitivity to acetaminophen or to any of the excipients in the formulation. Acetaminophen should be used with caution in patients with the following conditions: hepatic impairment or active hepatic disease, alcoholism, chronic malnutrition, severe hypovolemia, or severe renal impairment.

28

www.henryschein.com/aesthetics

12MS6370
Aesthetic Procedure & Treatment Guide

Table of Contents for the Digital Edition of Aesthetic Procedure & Treatment Guide
